{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:38:31Z","timestamp":1792607911313,"version":"4.5.0"},"reference-count":249,"publisher":"Portland Press Ltd.","issue":"8","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012025","name":"New York University Abu Dhabi","doi-asserted-by":"crossref","award":["AD055"],"award-info":[{"award-number":["AD055"]}],"id":[{"id":"10.13039\/100012025","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Coronaviruses constitute a significant threat to the human population. Severe acute respiratory syndrome coronavirus-2, SARS-CoV-2, is a highly pathogenic human coronavirus that has caused the coronavirus disease 2019 (COVID-19) pandemic. It has led to a global viral outbreak with an exceptional spread and a high death toll, highlighting the need for effective antiviral strategies. 3-Chymotrypsin-like protease (3CLpro), the main protease in SARS-CoV-2, plays an indispensable role in the SARS-CoV-2 viral life cycle by cleaving the viral polyprotein to produce 11 individual non-structural proteins necessary for viral replication. 3CLpro is one of two proteases that function to produce new viral particles. It is a highly conserved cysteine protease with identical structural folds in all known human coronaviruses. Inhibitors binding with high affinity to 3CLpro will prevent the cleavage of viral polyproteins, thus impeding viral replication. Multiple strategies have been implemented to screen for inhibitors against 3CLpro, including peptide-like and small molecule inhibitors that covalently and non-covalently bind the active site, respectively. In addition, allosteric sites of 3CLpro have been identified to screen for small molecules that could make non-competitive inhibitors of 3CLpro. In essence, this review serves as a comprehensive guide to understanding the structural intricacies and functional dynamics of 3CLpro, emphasizing key findings that elucidate its role as the main protease of SARS-CoV-2. Notably, the review is a critical resource in recognizing the advancements in identifying and developing 3CLpro inhibitors as effective antiviral strategies against COVID-19, some of which are already approved for clinical use in COVID-19 patients.<\/jats:p>","DOI":"10.1042\/bsr20231395","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T09:44:42Z","timestamp":1721641482000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["3-chymotrypsin-like protease in SARS-CoV-2"],"prefix":"10.1042","volume":"44","author":[{"given":"Kenana","family":"Al Adem","sequence":"first","affiliation":[{"name":"1Science Division, New York University Abu Dhabi, PO Box 129188, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana\u00a0C.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"1Science Division, New York University Abu Dhabi, PO Box 129188, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian\u00a0J.","family":"Villanueva","sequence":"additional","affiliation":[{"name":"1Science Division, New York University Abu Dhabi, PO Box 129188, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Fadl","sequence":"additional","affiliation":[{"name":"1Science Division, New York University Abu Dhabi, PO Box 129188, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"El-Sadaany","sequence":"additional","affiliation":[{"name":"1Science Division, New York University Abu Dhabi, PO Box 129188, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imen","family":"Masmoudi","sequence":"additional","affiliation":[{"name":"1Science Division, New York University Abu Dhabi, PO Box 129188, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugmee","family":"Gidiya","sequence":"additional","affiliation":[{"name":"1Science Division, New York University Abu Dhabi, PO Box 129188, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariro","family":"Gurudza","sequence":"additional","affiliation":[{"name":"1Science Division, New York University Abu Dhabi, PO Box 129188, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thyago\u00a0H.S.","family":"Cardoso","sequence":"additional","affiliation":[{"name":"2OMICS Centre of Excellence, G42 Healthcare, Masdar City, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin\u00a0K.","family":"Saksena","sequence":"additional","affiliation":[{"name":"3Victoria University, Footscray Campus, Melbourne, VIC. Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-8581","authenticated-orcid":false,"given":"Wael\u00a0M.","family":"Rabeh","sequence":"additional","affiliation":[{"name":"1Science Division, New York University Abu Dhabi, PO Box 129188, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"2024080512071844200_B1","first-page":"163","article-title":"Chapter Eight - Hosts and Sources of Endemic Human Coronaviruses","volume-title":"Advances in Virus Research. 100","author":"Corman","year":"2018"},{"key":"2024080512071844200_B2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"key":"2024080512071844200_B3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"2024080512071844200_B4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"2024080512071844200_B5","volume-title":"Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19)","author":"Aleem","year":"2023"},{"key":"2024080512071844200_B6","doi-asserted-by":"publisher","first-page":"166836","DOI":"10.1016\/j.bbadis.2023.166836","article-title":"SARS-CoV-2 variants, its recombinants and epigenomic exploitation of host defenses","volume":"1869","author":"Saksena","year":"2023","journal-title":"Biochim. Biophys. Acta"},{"key":"2024080512071844200_B7","doi-asserted-by":"publisher","first-page":"8078","DOI":"10.1038\/s41467-023-43703-3","article-title":"Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant","volume":"14","author":"Khan","year":"2023","journal-title":"Nat. Commun."},{"issue":"5","key":"2024080512071844200_B8","doi-asserted-by":"publisher","first-page":"BSR20201312","DOI":"10.1042\/BSR20201312","article-title":"A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity","volume":"40","author":"Saha","year":"2020","journal-title":"Biosci. Rep."},{"key":"2024080512071844200_B9","doi-asserted-by":"publisher","first-page":"109819","DOI":"10.1016\/j.envres.2020.109819","article-title":"Transmission of COVID-19 virus by droplets and aerosols: a critical review on the unresolved dichotomy","volume":"188","author":"Jayaweera","year":"2020","journal-title":"Environ. Res."},{"key":"2024080512071844200_B10","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s11845-020-02218-2","article-title":"COVID-19 may transmit through aerosol","volume":"189","author":"Wang","year":"2020","journal-title":"Ir. J. Med. Sci."},{"key":"2024080512071844200_B11","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41579-021-00535-6","article-title":"Transmissibility and transmission of respiratory viruses","volume":"19","author":"Leung","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"8","key":"2024080512071844200_B12","doi-asserted-by":"publisher","first-page":"BSR20211238","DOI":"10.1042\/BSR20211238","article-title":"Biochemical composition, transmission and diagnosis of SARS-CoV-2","volume":"41","author":"Ahirwar","year":"2021","journal-title":"Biosci. Rep."},{"key":"2024080512071844200_B13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12098-020-03263-6","article-title":"A review of coronavirus disease-2019 (COVID-19)","volume":"87","author":"Singhal","year":"2020","journal-title":"Indian J. Pediatr."},{"issue":"3","key":"2024080512071844200_B14","doi-asserted-by":"publisher","first-page":"BSR20222362","DOI":"10.1042\/BSR20222362","article-title":"Acid-base imbalance as a risk factor for mortality among COVID-19 hospitalized patients","volume":"43","author":"Al-Azzam","year":"2023","journal-title":"Biosci. Rep."},{"issue":"8","key":"2024080512071844200_B15","doi-asserted-by":"publisher","first-page":"BSR20210979","DOI":"10.1042\/BSR20210979","article-title":"Obesity, a major risk factor for immunity and severe outcomes of COVID-19","volume":"41","author":"Amin Mohammad","year":"2021","journal-title":"Biosci. Rep."},{"issue":"7","key":"2024080512071844200_B16","doi-asserted-by":"publisher","first-page":"BSR20210940","DOI":"10.1042\/BSR20210940","article-title":"Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19","volume":"41","author":"de Nooijer Aline","year":"2021","journal-title":"Biosci. Rep."},{"issue":"2","key":"2024080512071844200_B17","doi-asserted-by":"publisher","first-page":"BSR20203584","DOI":"10.1042\/BSR20203584","article-title":"Hyperglycemia at admission is a strong predictor of mortality and severe\/critical complications in COVID-19 patients: a meta-analysis","volume":"41","author":"Yang","year":"2021","journal-title":"Biosci. Rep."},{"issue":"12","key":"2024080512071844200_B18","doi-asserted-by":"publisher","first-page":"BSR20203455","DOI":"10.1042\/BSR20203455","article-title":"Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study","volume":"40","author":"Boari Gianluca","year":"2020","journal-title":"Biosci. Rep."},{"issue":"8","key":"2024080512071844200_B19","doi-asserted-by":"publisher","first-page":"BSR20200817","DOI":"10.1042\/BSR20200817","article-title":"Blood routine test in mild and common 2019 coronavirus (COVID-19) patients","volume":"40","author":"Djakpo","year":"2020","journal-title":"Biosci. Rep."},{"issue":"7","key":"2024080512071844200_B20","doi-asserted-by":"publisher","first-page":"BSR20230293","DOI":"10.1042\/BSR20230293","article-title":"COVID-19 associated thyroid dysfunction and other comorbidities and its management using phytochemical-based therapeutics: a natural way","volume":"43","author":"Parihar","year":"2023","journal-title":"Biosci. Rep."},{"issue":"8","key":"2024080512071844200_B21","doi-asserted-by":"publisher","first-page":"BSR20230595","DOI":"10.1042\/BSR20230595.","article-title":"The kynurenine pathway of tryptophan metabolism: a neglected therapeutic target of COVID-19 pathophysiology and immunotherapy","volume":"43","author":"Badawy Abdulla","year":"2023","journal-title":"Biosci. Rep."},{"key":"2024080512071844200_B22","doi-asserted-by":"publisher","first-page":"198882","DOI":"10.1016\/j.virusres.2022.198882","article-title":"Human coronaviruses: The emergence of SARS-CoV-2 and management of COVID-19","volume":"319","author":"Solomon","year":"2022","journal-title":"Virus Res."},{"key":"2024080512071844200_B23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3181\/00379727-121-30734","article-title":"A new virus isolated from the human respiratory tract","volume":"121","author":"Hamre","year":"1966","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"2024080512071844200_B24","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1073\/pnas.57.4.933","article-title":"Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease","volume":"57","author":"McIntosh","year":"1967","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2024080512071844200_B25","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nm1024","article-title":"Identification of a new human coronavirus","volume":"10","author":"van der Hoek","year":"2004","journal-title":"Nat. Med."},{"key":"2024080512071844200_B26","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1128\/JVI.79.2.884-895.2005","article-title":"Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia","volume":"79","author":"Woo","year":"2005","journal-title":"J. Virol."},{"key":"2024080512071844200_B27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1042\/CS20050188","article-title":"SARS: clinical presentation, transmission, pathogenesis and treatment options","volume":"110","author":"Chan Paul","year":"2006","journal-title":"Clin. Sci."},{"key":"2024080512071844200_B28","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"2024080512071844200_B29","doi-asserted-by":"publisher","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2024080512071844200_B30","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"issue":"12","key":"2024080512071844200_B31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3390\/ph13120447","article-title":"Inhibition of SARS-CoV-2 entry into host cells using small molecules","volume":"13","author":"Al Adem","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"2024080512071844200_B32","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.3390\/v6082991","article-title":"The coronavirus nucleocapsid is a multifunctional protein","volume":"6","author":"McBride","year":"2014","journal-title":"Viruses"},{"key":"2024080512071844200_B33","doi-asserted-by":"publisher","first-page":"9029","DOI":"10.1128\/JVI.01331-15","article-title":"The nucleocapsid protein of coronaviruses acts as a viral suppressor of RNA Silencing in mammalian cells","volume":"89","author":"Cui","year":"2015","journal-title":"J. Virol."},{"key":"2024080512071844200_B34","doi-asserted-by":"publisher","first-page":"114242","DOI":"10.1016\/j.biopha.2023.114242","article-title":"SARS-CoV-2 E protein: Pathogenesis and potential therapeutic development","volume":"159","author":"Zhou","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"2024080512071844200_B35","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/pro.4075","article-title":"Characterization of the SARS-CoV-2 E protein: sequence, structure, viroporin, and inhibitors","volume":"30","author":"Cao","year":"2021","journal-title":"Protein Sci."},{"key":"2024080512071844200_B36","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1099\/vir.0.80671-0","article-title":"Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E","volume":"86","author":"Nal","year":"2005","journal-title":"J. Gen. Virol."},{"key":"2024080512071844200_B37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jsb.2010.11.021","article-title":"A structural analysis of M protein in coronavirus assembly and morphology","volume":"174","author":"Neuman","year":"2011","journal-title":"J. Struct. Biol."},{"key":"2024080512071844200_B38","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"2024080512071844200_B39","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1126\/science.abb9983","article-title":"Site-specific glycan analysis of the SARS-CoV-2 spike","volume":"369","author":"Watanabe","year":"2020","journal-title":"Science"},{"key":"2024080512071844200_B40","doi-asserted-by":"publisher","first-page":"e00127","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"2024080512071844200_B41","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"key":"2024080512071844200_B42","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1164\/rccm.202001-0179LE","article-title":"Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2","volume":"202","author":"Zhao","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2024080512071844200_B43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2024080512071844200_B44","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41392-021-00653-w","article-title":"Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"2024080512071844200_B45","doi-asserted-by":"publisher","first-page":"100306","DOI":"10.1016\/j.jbc.2021.100306","article-title":"SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis","volume":"296","author":"Bayati","year":"2021","journal-title":"J. Biol. Chem."},{"key":"2024080512071844200_B46","doi-asserted-by":"publisher","first-page":"100721","DOI":"10.1016\/j.drup.2020.100721","article-title":"Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses","volume":"53","author":"Artese","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"2024080512071844200_B47","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bbrc.2020.02.071","article-title":"Structure analysis of the receptor binding of 2019-nCoV","volume":"525","author":"Chen","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2024080512071844200_B48","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","article-title":"Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein","volume":"17","author":"Xia","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"2024080512071844200_B49","doi-asserted-by":"publisher","first-page":"BSR20230504","DOI":"10.1042\/BSR20230504","article-title":"Surfactant replacement therapy as promising treatment for COVID-19: an updated narrative review","volume":"43","author":"Khudadah","year":"2023","journal-title":"Biosci. Rep."},{"key":"2024080512071844200_B50","doi-asserted-by":"publisher","first-page":"BSR20221927","DOI":"10.1042\/BSR20221927","article-title":"Polypharmacology of ambroxol in the treatment of COVID-19","volume":"43","author":"Wang","year":"2023","journal-title":"Biosci. Rep."},{"key":"2024080512071844200_B51","doi-asserted-by":"publisher","first-page":"BSR20212156","DOI":"10.1042\/BSR20212156","article-title":"Computational and in vitro experimental analyses of the anti-COVID-19 potential of Mortaparib and MortaparibPlus","volume":"41","author":"Kumar","year":"2021","journal-title":"Biosci. Rep."},{"key":"2024080512071844200_B52","doi-asserted-by":"publisher","first-page":"BSR20210611","DOI":"10.1042\/BSR20210611","article-title":"SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19","volume":"41","author":"Grobbelaar Lize","year":"2021","journal-title":"Biosci. Rep."},{"key":"2024080512071844200_B53","doi-asserted-by":"publisher","first-page":"BSR20202014","DOI":"10.1042\/BSR20202014","article-title":"ACE\/ACE2 balance might be instrumental to explain the certain comorbidities leading to severe COVID-19 cases","volume":"41","author":"Bank","year":"2021","journal-title":"Biosci. Rep."},{"key":"2024080512071844200_B54","doi-asserted-by":"publisher","first-page":"152302","DOI":"10.1016\/j.imbio.2022.152302","article-title":"A review on structural, non-structural, and accessory proteins of SARS-CoV-2: Highlighting drug target sites","volume":"228","author":"Jahirul Islam","year":"2023","journal-title":"Immunobiology"},{"key":"2024080512071844200_B55","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nrmicro2147","article-title":"Coronaviruses post-SARS: update on replication and pathogenesis","volume":"7","author":"Perlman","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"2024080512071844200_B56","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/jmv.25678","article-title":"Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle","volume":"92","author":"Lu","year":"2020","journal-title":"J. Med. Virol."},{"issue":"1","key":"2024080512071844200_B57","doi-asserted-by":"publisher","first-page":"BSR20231418","DOI":"10.1042\/BSR20231418","article-title":"SARS-CoV-2 NSP14 MTase activity is critical for inducing canonical NF-\u03baB activation","volume":"44","author":"Tofaute","year":"2023","journal-title":"Biosci. Rep."},{"key":"2024080512071844200_B58","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/0018578721999804","article-title":"Remdesivir","volume":"58","author":"Levien","year":"2023","journal-title":"Hosp. Pharm."},{"key":"2024080512071844200_B59","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"2024080512071844200_B60","doi-asserted-by":"publisher","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"2024080512071844200_B61","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.15190\/d.2022.10","article-title":"Remdesivir: the first FDA-approved anti-COVID-19 treatment for young children","volume":"10","author":"Chera","year":"2022","journal-title":"Discoveries (Craiova)"},{"key":"2024080512071844200_B62","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1042\/BCJ20200029","article-title":"Processing of the SARS-CoV pp1a\/ab nsp7-10 region","volume":"477","author":"Krichel","year":"2020","journal-title":"Biochem. J."},{"issue":"557","key":"2024080512071844200_B63","doi-asserted-by":"publisher","first-page":"eabc5332","DOI":"10.1126\/scitranslmed.abc5332","article-title":"3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice","volume":"12","author":"Rathnayake","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"2024080512071844200_B64","doi-asserted-by":"publisher","first-page":"e00505","DOI":"10.1128\/mSystems.00505-20","article-title":"Comparative genomic analysis of rapidly evolving SARS-CoV-2 reveals mosaic pattern of phylogeographical distribution","volume":"5","author":"Kumar","year":"2020","journal-title":"mSystems"},{"key":"2024080512071844200_B65","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/emboj\/cdf327","article-title":"Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain","volume":"21","author":"Anand","year":"2002","journal-title":"EMBO J."},{"issue":"4","key":"2024080512071844200_B66","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/jcm9041225","article-title":"The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control","volume":"9","author":"Helmy","year":"2020","journal-title":"J Clin Med."},{"key":"2024080512071844200_B67","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"3","key":"2024080512071844200_B68","doi-asserted-by":"publisher","first-page":"BSR20202616","DOI":"10.1042\/BSR20202616","article-title":"Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates","volume":"41","author":"Serafim","year":"2021","journal-title":"Biosci. Rep."},{"key":"2024080512071844200_B69","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1042\/BST20200396","article-title":"A pocket guide on how to structure SARS-CoV-2 drugs and therapies","volume":"48","author":"Littler","year":"2020","journal-title":"Biochem. Soc. Trans."},{"key":"2024080512071844200_B70","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"11","key":"2024080512071844200_B71","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1042\/BCJ20230027","article-title":"Key allosteric and active site residues of SARS-CoV-2 3CLpro Are Promising Drug Targets","volume":"480","author":"Al Adem","year":"2023","journal-title":"Biochem. J."},{"key":"2024080512071844200_B72","doi-asserted-by":"publisher","first-page":"e77433","DOI":"10.7554\/eLife.77433","article-title":"Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms","volume":"11","author":"Flynn","year":"2022","journal-title":"eLife"},{"key":"2024080512071844200_B73","first-page":"102790","article-title":"pH profiles of 3-chymotrypsin-like protease (3CLpro) from SARS-CoV-2 elucidate its catalytic mechanism and a histidine residue critical for activity","author":"Al Adem","year":"2022","journal-title":"J. Biol. Chem."},{"key":"2024080512071844200_B74","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1038\/s41467-020-16954-7","article-title":"Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography","volume":"11","author":"Kneller","year":"2020","journal-title":"Nat. Commun."},{"key":"2024080512071844200_B75","doi-asserted-by":"publisher","first-page":"104697","DOI":"10.1016\/j.jbc.2023.104697","article-title":"SARS-CoV-2 polyprotein substrate regulates the stepwise M(pro) cleavage reaction","volume":"299","author":"Narwal","year":"2023","journal-title":"J. Biol. Chem."},{"key":"2024080512071844200_B76","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1038\/s41467-022-31210-w","article-title":"Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance","volume":"13","author":"Shaqra","year":"2022","journal-title":"Nat. Commun."},{"key":"2024080512071844200_B77","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"2024080512071844200_B78","doi-asserted-by":"publisher","first-page":"10626","DOI":"10.1039\/D0SC02823A","article-title":"Revealing the molecular mechanisms of proteolysis of SARS-CoV-2 Mpro by QM\/MM computational methods","volume":"11","author":"\u015awiderek","year":"2020","journal-title":"Chem. Sci."},{"key":"2024080512071844200_B79","doi-asserted-by":"publisher","first-page":"167118","DOI":"10.1016\/j.jmb.2021.167118","article-title":"A Crystallographic Snapshot of SARS-CoV-2 Main Protease Maturation Process","volume":"433","author":"Noske","year":"2021","journal-title":"J. Mol. Biol."},{"key":"2024080512071844200_B80","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1038\/s41467-020-18709-w","article-title":"Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease","volume":"11","author":"Douangamath","year":"2020","journal-title":"Nat. Commun."},{"key":"2024080512071844200_B81","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"2024080512071844200_B82","doi-asserted-by":"publisher","first-page":"e2117142119","DOI":"10.1073\/pnas.2117142119","article-title":"Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2","volume":"119","author":"Zhao","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2024080512071844200_B83","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"2024080512071844200_B84","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V'Kovski","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"2024080512071844200_B85","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1042\/BCJ20200029","article-title":"Processing of the SARS-CoV pp1a\/ab nsp7-10 region","volume":"477","author":"Krichel","year":"2020","journal-title":"Biochem. J."},{"key":"2024080512071844200_B86","doi-asserted-by":"publisher","first-page":"e106275","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J."},{"key":"2024080512071844200_B87","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1042\/BCJ20210256","article-title":"An all-out assault on SARS-CoV-2 replication","volume":"478","author":"Hay","year":"2021","journal-title":"Biochem. J."},{"key":"2024080512071844200_B88","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1038\/s41467-020-16954-7","article-title":"Structural plasticity of SARS-CoV-2 3CL M(pro) active site cavity revealed by room temperature X-ray crystallography","volume":"11","author":"Kneller","year":"2020","journal-title":"Nat. Commun."},{"key":"2024080512071844200_B89","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/BF02174046","article-title":"Viral cysteine proteinases","volume":"6","author":"Gorbalenya","year":"1996","journal-title":"Perspect. Drug Discov. Des."},{"key":"2024080512071844200_B90","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fphar.2016.00107","article-title":"Cysteine Proteases: modes of activation and future prospects as pharmacological targets","volume":"7","author":"Verma","year":"2016","journal-title":"Front Pharmacol."},{"key":"2024080512071844200_B91","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1107\/S1399004715003521","article-title":"Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity","volume":"71","author":"Needle","year":"2015","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"2024080512071844200_B92","doi-asserted-by":"publisher","first-page":"692168","DOI":"10.3389\/fchem.2021.692168","article-title":"Catalytic dyad residues His41 and Cys145 impact the catalytic activity and overall conformational fold of the main SARS-CoV-2 protease 3-chymotrypsin-like protease","volume":"9","author":"Ferreira","year":"2021","journal-title":"Front Chem."},{"key":"2024080512071844200_B93","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/B978-0-12-818168-3.00002-4","article-title":"Chapter 2 - Potential roles of protease inhibitors in anticancer therapy","volume-title":"Cancer-Leading Proteases","author":"Trezza","year":"2020"},{"key":"2024080512071844200_B94","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.virol.2009.03.034","article-title":"Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure","volume":"388","author":"Hu","year":"2009","journal-title":"Virology"},{"key":"2024080512071844200_B95","doi-asserted-by":"publisher","first-page":"31257","DOI":"10.1074\/jbc.M502577200","article-title":"Mechanism of the maturation process of SARS-CoV 3CL protease","volume":"280","author":"Hsu","year":"2005","journal-title":"J. Biol. Chem."},{"key":"2024080512071844200_B96","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1021\/bi036022q","article-title":"3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism","volume":"43","author":"Huang","year":"2004","journal-title":"Biochemistry"},{"key":"2024080512071844200_B97","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1073\/pnas.0510851103","article-title":"Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme","volume":"103","author":"Ratia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2024080512071844200_B98","doi-asserted-by":"publisher","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2024080512071844200_B99","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.virusres.2007.02.015","article-title":"Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery","volume":"133","author":"Grum-Tokars","year":"2008","journal-title":"Virus Res."},{"key":"2024080512071844200_B100","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1074\/jbc.M310875200","article-title":"Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase","volume":"279","author":"Fan","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"4","key":"2024080512071844200_B101","doi-asserted-by":"publisher","first-page":"e02577","DOI":"10.1128\/AAC.02577-20","article-title":"Kinetic characterization and inhibitor screening for the proteases leading to identification of drugs against SARS-CoV-2","volume":"65","author":"Kuo","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"2024080512071844200_B102","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1042\/BCJ20220105","article-title":"Development of a colorimetric assay for the detection of SARS-CoV-2 3CLpro activity","volume":"479","author":"Garland","year":"2022","journal-title":"Biochem. J."},{"key":"2024080512071844200_B103","doi-asserted-by":"publisher","first-page":"102326","DOI":"10.1016\/j.xpro.2023.102326","article-title":"Protocol for production and purification of SARS-CoV-2 3CLpro","volume":"4","author":"Mazzei","year":"2023","journal-title":"STAR Protocols"},{"key":"2024080512071844200_B104","doi-asserted-by":"publisher","first-page":"101158","DOI":"10.1016\/j.xpro.2022.101158","article-title":"Protocol for structure determination of SARS-CoV-2 main protease at near-physiological-temperature by serial femtosecond crystallography","volume":"3","author":"Ertem","year":"2022","journal-title":"STAR Protoc."},{"key":"2024080512071844200_B105","doi-asserted-by":"publisher","first-page":"6718","DOI":"10.3390\/ijms16046718","article-title":"Understanding FRET as a research tool for cellular studies","volume":"16","author":"Shrestha","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"2024080512071844200_B106","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.febslet.2004.09.026","article-title":"Characterization of SARS-CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence-based assay","volume":"576","author":"Kao","year":"2004","journal-title":"FEBS Lett."},{"issue":"8","key":"2024080512071844200_B107","doi-asserted-by":"publisher","first-page":"e21774","DOI":"10.1096\/fj.202100994","article-title":"Dimethyl sulfoxide reduces the stability but enhances catalytic activity of the main SARS-CoV-2 protease 3CLpro","volume":"35","author":"Ferreira","year":"2021","journal-title":"FASEB J."},{"key":"2024080512071844200_B108","doi-asserted-by":"publisher","first-page":"22200","DOI":"10.1038\/s41598-020-79357-0","article-title":"Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2","volume":"10","author":"Ferreira","year":"2020","journal-title":"Sci. Rep."},{"key":"2024080512071844200_B109","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/s41598-022-05424-3","article-title":"Pro108Ser mutation of SARS-CoV-2 3CL(pro) reduces the enzyme activity and ameliorates the clinical severity of COVID-19","volume":"12","author":"Abe","year":"2022","journal-title":"Sci. Rep."},{"key":"2024080512071844200_B110","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41422-022-00640-y","article-title":"The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition","volume":"32","author":"Sacco","year":"2022","journal-title":"Cell Res."},{"key":"2024080512071844200_B111","doi-asserted-by":"publisher","first-page":"128629","DOI":"10.1016\/j.bmcl.2022.128629","article-title":"Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir","volume":"62","author":"Ullrich","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"2024080512071844200_B112","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","article-title":"Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir","volume":"9","author":"Hu","year":"2022","journal-title":"ACS Cent. Sci."},{"key":"2024080512071844200_B113","doi-asserted-by":"publisher","first-page":"103004","DOI":"10.1016\/j.jbc.2023.103004","article-title":"Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease","volume":"299","author":"Noske","year":"2023","journal-title":"J. Biol. Chem."},{"key":"2024080512071844200_B114","doi-asserted-by":"publisher","first-page":"e81334","DOI":"10.7554\/eLife.81334","article-title":"Developing evolution-resistant drugs for COVID-19","volume":"11","author":"Weinreich","year":"2022","journal-title":"Elife"},{"key":"2024080512071844200_B115","doi-asserted-by":"publisher","first-page":"313","DOI":"10.4014\/jmb.2003.03011","article-title":"Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19)","volume":"30","author":"Ahn","year":"2020","journal-title":"J. Microbiol. Biotech."},{"issue":"4","key":"2024080512071844200_B116","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3390\/biom11040607","article-title":"SARS-CoV-2 M(pro): a potential target for peptidomimetics and small-molecule inhibitors","volume":"11","author":"Citarella","year":"2021","journal-title":"Biomolecules"},{"key":"2024080512071844200_B117","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.csbj.2022.03.009","article-title":"Inhibition of the main protease of SARS-CoV-2 (M(pro)) by repurposing\/designing drug-like substances and utilizing nature's toolbox of bioactive compounds","volume":"20","author":"Antonopoulou","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"2024080512071844200_B118","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1002\/mco2.151","article-title":"The SARS-CoV-2 main protease (M(pro)): Structure, function, and emerging therapies for COVID-19","volume":"3","author":"Hu","year":"2022","journal-title":"MedComm (2020)"},{"key":"2024080512071844200_B119","first-page":"1","article-title":"Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists","volume":"46","author":"Copeland","year":"2005","journal-title":"Methods Biochem. Anal."},{"key":"2024080512071844200_B120","first-page":"3396","article-title":"Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL(pro)): an in silico screening of alkaloids and terpenoids from African medicinal plants","volume":"39","author":"Gyebi","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"2024080512071844200_B121","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/9781119851042.ch13","article-title":"Enzyme Inhibition","author":"Hollenberg","year":"2022","journal-title":"Drug Metabolism Handbook"},{"issue":"1","key":"2024080512071844200_B122","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1039\/D2MD00344A","article-title":"Advances in research on 3C-like protease (3CLpro) inhibitors against SARS-CoV-2 since 2020","volume":"14","author":"Chen","year":"2023","journal-title":"RSC Medicinal Chemistry"},{"key":"2024080512071844200_B123","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejmech.2017.06.019","article-title":"Covalent inhibitors design and discovery","volume":"138","author":"De Cesco","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"2024080512071844200_B124","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"2024080512071844200_B125","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10930-020-09884-2","article-title":"Covalent versus non-covalent enzyme inhibition: which route should we take? a justification of the good and bad from molecular modelling perspective","volume":"39","author":"Aljoundi","year":"2020","journal-title":"Protein J."},{"key":"2024080512071844200_B126","volume-title":"Smith and Williams' Introduction to the Principles of Drug Design and Action","author":"Smith","year":"1998","edition":"4th ed."},{"key":"2024080512071844200_B127","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/B0-08-045044-X\/00052-3","article-title":"2.15 - Peptidomimetic and Nonpeptide Drug Discovery: Receptor, Protease, and Signal Transduction Therapeutic Targets","volume-title":"Comprehensive Medicinal Chemistry II","author":"Sawyer","year":"2007"},{"key":"2024080512071844200_B128","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"2024080512071844200_B129","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1021\/acsptsci.2c00065","article-title":"The remarkable selectivity of nirmatrelvir","volume":"5","author":"Duveau","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"2024080512071844200_B130","doi-asserted-by":"publisher","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3cl proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"key":"2024080512071844200_B131","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01819-20","article-title":"A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL(pro) inhibitor PF-00835231 as a potential new treatment for COVID-19","volume":"95","author":"de Vries","year":"2021","journal-title":"J. Virol."},{"key":"2024080512071844200_B132","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir plus ritonavir: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"2024080512071844200_B133","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"2024080512071844200_B134","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2165\/00003495-200363080-00004","article-title":"Lopinavir\/ritonavir: a review of its use in the management of HIV infection","volume":"63","author":"Cvetkovic","year":"2003","journal-title":"Drugs"},{"key":"2024080512071844200_B135","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2024080512071844200_B136","doi-asserted-by":"publisher","first-page":"167706","DOI":"10.1016\/j.jmb.2022.167706","article-title":"Structural basis of main proteases of coronavirus bound to drug candidate PF-07304814","volume":"434","author":"Li","year":"2022","journal-title":"J. Mol. Biol."},{"key":"2024080512071844200_B137","doi-asserted-by":"publisher","first-page":"6055","DOI":"10.1038\/s41467-021-26239-2","article-title":"Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19","volume":"12","author":"Boras","year":"2021","journal-title":"Nat. Commun."},{"key":"2024080512071844200_B138","doi-asserted-by":"publisher","first-page":"1035969","DOI":"10.3389\/fphar.2022.1035969","article-title":"Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol."},{"key":"2024080512071844200_B139","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.2c00375","article-title":"Early clinical development of lufotrelvir as a potential therapy for COVID-19","author":"Allais","year":"2023","journal-title":"Org. Process Res. Dev."},{"key":"2024080512071844200_B140","doi-asserted-by":"publisher","first-page":"ofad355","DOI":"10.1093\/ofid\/ofad355","article-title":"Safety, tolerability, and pharmacokinetics of single and multiple ascending intravenous infusions of PF-07304814 (Lufotrelvir) in participants hospitalized with COVID-19","volume":"10","author":"Robinson","year":"2023","journal-title":"Open Forum Infect Dis."},{"key":"2024080512071844200_B141","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1038\/s41467-020-18096-2","article-title":"Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"11","author":"Vuong","year":"2020","journal-title":"Nat. Commun."},{"key":"2024080512071844200_B142","doi-asserted-by":"publisher","first-page":"167003","DOI":"10.1016\/j.jmb.2021.167003","article-title":"N-terminal finger stabilizes the S1 pocket for the reversible feline drug GC376 in the SARS-CoV-2 M(pro) dimer","volume":"433","author":"Arutyunova","year":"2021","journal-title":"J. Mol. Biol."},{"key":"2024080512071844200_B143","doi-asserted-by":"publisher","first-page":"105020","DOI":"10.1016\/j.antiviral.2021.105020","article-title":"Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development","volume":"187","author":"Liu","year":"2021","journal-title":"Antiviral Res."},{"key":"2024080512071844200_B144","doi-asserted-by":"publisher","DOI":"10.3390\/v15030781","article-title":"Crystal structures of inhibitor-bound main protease from delta- and gamma-coronaviruses","volume":"15","author":"Zvornicanin","year":"2023","journal-title":"Viruses"},{"key":"2024080512071844200_B145","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/s41467-021-22362-2","article-title":"Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors","volume":"12","author":"Iketani","year":"2021","journal-title":"Nat. Commun."},{"key":"2024080512071844200_B146","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"issue":"29","key":"2024080512071844200_B147","doi-asserted-by":"publisher","first-page":"e2101555118","DOI":"10.1073\/pnas.2101555118","article-title":"Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection","volume":"118","author":"Dampalla","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2024080512071844200_B148","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/cmdc.202000924","article-title":"A quick route to multiple highly potent SARS-CoV-2 main protease inhibitors*","volume":"16","author":"Yang","year":"2021","journal-title":"Chem. Med. Chem."},{"key":"2024080512071844200_B149","doi-asserted-by":"publisher","first-page":"10047","DOI":"10.1021\/acs.jmedchem.1c00319","article-title":"Structure-guided design of conformationally constrained cyclohexane inhibitors of severe acute respiratory syndrome coronavirus-2 3CL protease","volume":"64","author":"Dampalla","year":"2021","journal-title":"J. Med. Chem."},{"key":"2024080512071844200_B150","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"\u03b1-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"key":"2024080512071844200_B151","doi-asserted-by":"publisher","first-page":"5788","DOI":"10.2174\/0929867328666210104110053","article-title":"The therapeutic use of the zonulin inhibitor AT-1001 (Larazotide) for a variety of acute and chronic inflammatory diseases","volume":"28","author":"Troisi","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"2024080512071844200_B152","doi-asserted-by":"publisher","first-page":"114857","DOI":"10.1016\/j.ejmech.2022.114857","article-title":"Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2","volume":"244","author":"Di Micco","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"2024080512071844200_B153","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1039\/D0MD00367K","article-title":"Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics","volume":"12","author":"Oerlemans","year":"2020","journal-title":"RSC Med Chem."},{"key":"2024080512071844200_B154","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.tips.2012.03.012","article-title":"Discovery of boceprevir, a direct-acting NS3\/4A protease inhibitor for treatment of chronic hepatitis C infections","volume":"33","author":"Venkatraman","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"2024080512071844200_B155","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","author":"Fu","year":"2020","journal-title":"Nat Commun."},{"key":"2024080512071844200_B156","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1021\/acs.jcim.0c01457","article-title":"Targeting SARS-CoV-2 M3CLpro by HCV NS3\/4a Inhibitors: In Silico Modeling and In Vitro Screening","volume":"61","author":"Manandhar","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"2024080512071844200_B157","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00468-9","article-title":"Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir","volume":"6","author":"Bai","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"2024080512071844200_B158","doi-asserted-by":"publisher","first-page":"114596","DOI":"10.1016\/j.ejmech.2022.114596","article-title":"A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals","volume":"240","author":"Alugubelli","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"2024080512071844200_B159","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.3390\/molecules27134292","article-title":"From repurposing to redesign: optimization of boceprevir to highly potent inhibitors of the SARS-CoV-2 main protease","volume":"27","author":"G\u00f6hl","year":"2022","journal-title":"Molecules"},{"key":"2024080512071844200_B160","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1038\/s41467-022-29915-z","article-title":"Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease","volume":"13","author":"Kneller","year":"2022","journal-title":"Nat. Commun."},{"key":"2024080512071844200_B161","doi-asserted-by":"publisher","first-page":"6463","DOI":"10.1038\/s41467-023-42102-y","article-title":"Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat. Commun."},{"key":"2024080512071844200_B162","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa2301425","article-title":"Oral simnotrelvir for adult patients with mild-to-moderate Covid-19","volume":"390","author":"Cao","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"2024080512071844200_B163","doi-asserted-by":"publisher","first-page":"eadi0979","DOI":"10.1126\/scitranslmed.adi0979","article-title":"An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations","volume":"16","author":"Westberg","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"2024080512071844200_B164","doi-asserted-by":"publisher","first-page":"102359","DOI":"10.1016\/j.eclinm.2023.102359","article-title":"Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial","volume":"67","author":"Zhan","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2024080512071844200_B165","doi-asserted-by":"publisher","first-page":"2023.03.09.531862","DOI":"10.1101\/2023.03.09.531862","article-title":"Inhibition mechanism and antiviral activity of an \u03b1-ketoamide based SARS-CoV-2 main protease inhibitor","author":"Chen","year":"2023","journal-title":"bioRxiv"},{"key":"2024080512071844200_B166","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s42003-020-01577-x","article-title":"Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents","volume":"4","author":"Mody","year":"2021","journal-title":"Commun. Biol."},{"key":"2024080512071844200_B167","doi-asserted-by":"publisher","first-page":"e07962","DOI":"10.1016\/j.heliyon.2021.e07962","article-title":"Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies","volume":"7","author":"Mahmoud","year":"2021","journal-title":"Heliyon"},{"key":"2024080512071844200_B168","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1021\/acsptsci.1c00099","article-title":"Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir","volume":"4","author":"Xia","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"2024080512071844200_B169","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model","volume":"371","author":"Qiao","year":"2021","journal-title":"Science"},{"key":"2024080512071844200_B170","doi-asserted-by":"publisher","first-page":"20697","DOI":"10.1021\/jacs.1c08060","article-title":"Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity","volume":"143","author":"Ma","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"2024080512071844200_B171","doi-asserted-by":"publisher","first-page":"115667","DOI":"10.1016\/j.ejmech.2023.115667","article-title":"Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors","volume":"259","author":"Tan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"2024080512071844200_B172","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.coviro.2021.04.006","article-title":"Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection","volume":"49","author":"Vandyck","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"2024080512071844200_B173","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1128\/AAC.47.12.3907-3916.2003","article-title":"Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers","volume":"47","author":"Hayden","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"2024080512071844200_B174","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1128\/AAC.49.6.2267-2275.2005","article-title":"In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease","volume":"49","author":"Patick","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"2024080512071844200_B175","doi-asserted-by":"publisher","first-page":"105458","DOI":"10.1016\/j.antiviral.2022.105458","article-title":"Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404","volume":"208","author":"F\u00e0brega-Ferrer","year":"2022","journal-title":"Antiviral Res."},{"key":"2024080512071844200_B176","doi-asserted-by":"publisher","first-page":"114046","DOI":"10.1016\/j.ejmech.2021.114046","article-title":"Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CL(pro) covalent inhibitors","volume":"229","author":"Stille","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"2024080512071844200_B177","doi-asserted-by":"publisher","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J. Med. Chem."},{"key":"2024080512071844200_B178","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2147\/DDDT.S359009","article-title":"Progress on SARS-CoV-2 3CLpro inhibitors: inspiration from SARS-CoV 3CLpro peptidomimetics and small-molecule anti-inflammatory compounds","volume":"16","author":"Zhu","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"2024080512071844200_B179","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1126\/science.abf7945","article-title":"X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease","volume":"372","author":"G\u00fcnther","year":"2021","journal-title":"Science"},{"key":"2024080512071844200_B180","doi-asserted-by":"publisher","first-page":"23492","DOI":"10.1002\/anie.202107481","article-title":"Repurposing an antiviral drug against SARS-CoV-2 main protease","volume":"60","author":"Sarkar","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2024080512071844200_B181","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1021\/cr000426w","article-title":"Chemistry of biologically important synthetic organoselenium compounds","volume":"101","author":"Mugesh","year":"2001","journal-title":"Chem. Rev."},{"key":"2024080512071844200_B182","doi-asserted-by":"publisher","first-page":"9161","DOI":"10.1038\/s41598-023-35907-w","article-title":"Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PLpro and Mpro proteases, and nsp14 guanine N7-methyltransferase","volume":"13","author":"Zmudzinski","year":"2023","journal-title":"Sci. Rep."},{"key":"2024080512071844200_B183","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1371\/journal.pbio.0030324","article-title":"Design of wide-spectrum inhibitors targeting coronavirus main proteases","volume":"3","author":"Yang","year":"2005","journal-title":"PLoS Biol."},{"key":"2024080512071844200_B184","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41594-020-0440-6","article-title":"Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur","volume":"27","author":"Jin","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2024080512071844200_B185","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ejmech.2017.05.045","article-title":"Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study","volume":"137","author":"Wang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"2024080512071844200_B186","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1021\/acsptsci.2c00203","article-title":"Detailed Insights into the Inhibitory Mechanism of New Ebselen Derivatives against Main Protease (M(pro)) of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)","volume":"6","author":"Sahoo","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"2024080512071844200_B187","doi-asserted-by":"publisher","first-page":"115720","DOI":"10.1016\/j.ejmech.2023.115720","article-title":"Discovery of antiviral SARS-CoV-2 main protease inhibitors by structure-guided hit-to-lead optimization of carmofur","volume":"260","author":"Kang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"2024080512071844200_B188","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/antibiotics12030524","article-title":"Disulfiram: mechanisms, applications, and challenges","volume":"12","author":"Lanz","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2024080512071844200_B189","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1021\/acsptsci.0c00130","article-title":"Ebselen, disulfiram, carmofur, PX-12, Tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors","volume":"3","author":"Ma","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"2024080512071844200_B190","doi-asserted-by":"publisher","first-page":"e0259061","DOI":"10.1371\/journal.pone.0259061","article-title":"Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study","volume":"16","author":"Fillmore","year":"2021","journal-title":"PloS ONE"},{"key":"2024080512071844200_B191","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s11739-021-02633-y","article-title":"COVID-19 and related symptoms in patients under disulfiram for alcohol use disorder","volume":"16","author":"Tamburin","year":"2021","journal-title":"Intern Emerg. Med."},{"key":"2024080512071844200_B192","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1039\/D0MD00154F","article-title":"Covalent inhibitors: a rational approach to drug discovery","volume":"11","author":"Sutanto","year":"2020","journal-title":"RSC Med. Chem."},{"key":"2024080512071844200_B193","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.2174\/1381612811319220016","article-title":"Non-covalent proteasome inhibitors","volume":"19","author":"Kaffy","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"2024080512071844200_B194","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.4155\/fmc-2020-0118","article-title":"Covalent inhibitors: back on track?","volume":"12","author":"Gehringer","year":"2020","journal-title":"Future Med. Chem."},{"key":"2024080512071844200_B195","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","article-title":"Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies","volume":"14","author":"Gu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"2024080512071844200_B196","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"2024080512071844200_B197","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s42003-023-05071-y","article-title":"Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants","volume":"6","author":"Lin","year":"2023","journal-title":"Commun. Biol."},{"key":"2024080512071844200_B198","doi-asserted-by":"publisher","first-page":"e0069722","DOI":"10.1128\/aac.00697-22","article-title":"A Randomized Phase 2\/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part","volume":"66","author":"Mukae","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"2024080512071844200_B199","doi-asserted-by":"publisher","first-page":"823.e5","DOI":"10.1016\/j.str.2021.06.002","article-title":"Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease","volume":"29","author":"Deshmukh","year":"2021","journal-title":"Structure"},{"key":"2024080512071844200_B200","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1021\/acs.jmedchem.1c00598","article-title":"Structure-based optimization of ML300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3CL protease (SARS-CoV-2 3CL(pro))","volume":"65","author":"Han","year":"2022","journal-title":"J. Med. Chem."},{"key":"2024080512071844200_B201","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1021\/jm301580n","article-title":"Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease","volume":"56","author":"Jacobs","year":"2013","journal-title":"J. Med. Chem."},{"key":"2024080512071844200_B202","doi-asserted-by":"publisher","DOI":"10.3390\/v13020174","article-title":"Crystal structure of SARS-CoV-2 main protease in complex with the non-covalent inhibitor ML188","volume":"13","author":"Lockbaum","year":"2021","journal-title":"Viruses"},{"key":"2024080512071844200_B203","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1021\/acs.jmedchem.1c00509","article-title":"Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors","volume":"65","author":"Kitamura","year":"2022","journal-title":"J. Med. Chem."},{"key":"2024080512071844200_B204","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1021\/acs.jcim.1c00851","article-title":"High-throughput virtual screening and validation of a SARS-CoV-2 main protease noncovalent inhibitor","volume":"62","author":"Clyde","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"2024080512071844200_B205","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1126\/science.abg5827","article-title":"Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2","volume":"373","author":"Drayman","year":"2021","journal-title":"Science"},{"key":"2024080512071844200_B206","doi-asserted-by":"publisher","first-page":"114378","DOI":"10.1016\/j.biopha.2023.114378","article-title":"Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series","volume":"160","author":"Ketabforoush","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"2024080512071844200_B207","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1021\/acs.jcim.3c00324","article-title":"Targeting SARS-CoV-2 Main Protease (MPro) with Kinase Inhibitors: A Promising Approach for Discovering Antiviral and Anti-inflammatory Molecules against SARS-CoV-2","volume":"63","author":"Anton","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"2024080512071844200_B208","doi-asserted-by":"publisher","first-page":"13768","DOI":"10.3390\/ijms150813768","article-title":"Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies","volume":"15","author":"Hojjat-Farsangi","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"2024080512071844200_B209","doi-asserted-by":"publisher","first-page":"101489","DOI":"10.1016\/j.eclinm.2022.101489","article-title":"Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials","volume":"49","author":"Selvaraj","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2024080512071844200_B210","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijbiomac.2021.02.012","article-title":"Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2","volume":"176","author":"Du","year":"2021","journal-title":"Int. J. Bio. Macromo."},{"key":"2024080512071844200_B211","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.bbrc.2020.12.106","article-title":"The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease","volume":"591","author":"Chiou","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2024080512071844200_B212","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.ijbiomac.2020.07.235","article-title":"Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening","volume":"164","author":"Abian","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"issue":"4","key":"2024080512071844200_B213","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/biomedicines9040375","article-title":"Rutin is a low micromolar inhibitor of SARS-CoV-2 main protease 3CLpro: implications for drug design of quercetin analogs","volume":"9","author":"Rizzuti","year":"2021","journal-title":"Biomedicines"},{"key":"2024080512071844200_B214","doi-asserted-by":"publisher","first-page":"131594","DOI":"10.1016\/j.foodchem.2021.131594","article-title":"Inhibition of the SARS-CoV-2 3CL(pro) main protease by plant polyphenols","volume":"373","author":"Bahun","year":"2022","journal-title":"Food Chem."},{"key":"2024080512071844200_B215","doi-asserted-by":"publisher","first-page":"2020.04.13.038687","DOI":"10.1101\/2020.04.13.038687","article-title":"Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro","author":"Su","year":"2020","journal-title":"bioRxiv"},{"key":"2024080512071844200_B216","doi-asserted-by":"publisher","first-page":"22796","DOI":"10.1038\/s41598-021-02266-3","article-title":"An integrated method for optimized identification of effective natural inhibitors against SARS-CoV-2 3CLpro","volume":"11","author":"Liao","year":"2021","journal-title":"Sci. Rep."},{"key":"2024080512071844200_B217","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1755-5949.2008.00045.x","article-title":"Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases","volume":"14","author":"Rocha-Gonz\u00e1lez","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"2024080512071844200_B218","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ifset.2009.07.002","article-title":"Antioxidant properties of resveratrol: a structure-activity insight","volume":"11","author":"G\u00fcl\u00e7in","year":"2010","journal-title":"Innovative Food Sci. Emerging Technologies"},{"key":"2024080512071844200_B219","first-page":"196","article-title":"Antioxidants and cancer, part 3: quercetin","volume":"5","author":"Lamson","year":"2000","journal-title":"Altern. Med. Rev."},{"key":"2024080512071844200_B220","doi-asserted-by":"publisher","first-page":"16785","DOI":"10.3390\/ijms131216785","article-title":"Antiviral activity of baicalein and quercetin against the Japanese encephalitis virus","volume":"13","author":"Johari","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"2024080512071844200_B221","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s13318-018-0509-3","article-title":"Pharmacokinetics and bioavailability enhancement of baicalin: a review","volume":"44","author":"Huang","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"2024080512071844200_B222","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.2147\/IJGM.S318949","article-title":"Potential clinical benefits of quercetin in the early stage of COVID-19: results of a second, pilot, randomized, controlled and open-label clinical trial","volume":"14","author":"Di Pierro","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"2024080512071844200_B223","doi-asserted-by":"publisher","first-page":"1096853","DOI":"10.3389\/fphar.2022.1096853","article-title":"Quercetin as a possible complementary agent for early-stage COVID-19: concluding results of a randomized clinical trial","volume":"13","author":"Di Pierro","year":"2022","journal-title":"Front Pharmacol."},{"issue":"5","key":"2024080512071844200_B224","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3390\/antiox11050876","article-title":"The therapeutic and prophylactic potential of quercetin against COVID-19: an outlook on the clinical studies, inventive compositions, and patent literature","volume":"11","author":"Imran","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"2024080512071844200_B225","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/ptr.6916","article-title":"Resveratrol inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cultured Vero cells","volume":"35","author":"Yang","year":"2021","journal-title":"Phytother. Res."},{"issue":"2","key":"2024080512071844200_B226","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/v13020354","article-title":"Resveratrol inhibits HCoV-229E and SARS-CoV-2 coronavirus replication in vitro","volume":"13","author":"Pasquereau","year":"2021","journal-title":"Viruses"},{"key":"2024080512071844200_B227","doi-asserted-by":"publisher","first-page":"10978","DOI":"10.1038\/s41598-022-13920-9","article-title":"Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19)","volume":"12","author":"McCreary","year":"2022","journal-title":"Sci. Rep."},{"issue":"22","key":"2024080512071844200_B228","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.3390\/molecules26226900","article-title":"Curcumin inhibits in vitro SARS-CoV-2 infection in vero E6 cells through multiple antiviral mechanisms","volume":"26","author":"Mar\u00edn-Palma","year":"2021","journal-title":"Molecules"},{"issue":"13","key":"2024080512071844200_B229","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.3390\/molecules26133962","article-title":"Antiviral effects of green tea EGCG and its potential application against COVID-19","volume":"26","author":"Wang","year":"2021","journal-title":"Molecules"},{"key":"2024080512071844200_B230","doi-asserted-by":"publisher","first-page":"5630838","DOI":"10.1155\/2020\/5630838","article-title":"Tea polyphenols EGCG and theaflavin inhibit the activity of SARS-CoV-2 3CL-protease in vitro","volume":"2020","author":"Jang","year":"2020","journal-title":"Evid. Based Complement Alternat. Med."},{"key":"2024080512071844200_B231","doi-asserted-by":"publisher","first-page":"6405","DOI":"10.1021\/acs.jmedchem.8b01749","article-title":"Allosteric modulator discovery: from serendipity to structure-based design","volume":"62","author":"Lu","year":"2019","journal-title":"J. Med. Chem."},{"key":"2024080512071844200_B232","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1742-4658.2006.05130.x","article-title":"The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain","volume":"273","author":"Shi","year":"2006","journal-title":"FEBS J."},{"key":"2024080512071844200_B233","doi-asserted-by":"publisher","first-page":"102023","DOI":"10.1016\/j.jbc.2022.102023","article-title":"Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2","volume":"298","author":"Ferreira","year":"2022","journal-title":"J. Biol. Chem."},{"key":"2024080512071844200_B234","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1021\/bi1002585","article-title":"Mutation of Asn28 disrupts the dimerization and enzymatic activity of SARS 3CL(pro)","volume":"49","author":"Barrila","year":"2010","journal-title":"Biochemistry"},{"key":"2024080512071844200_B235","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.1128\/JVI.02680-07","article-title":"Mechanism for controlling the dimer-monomer switch and coupling dimerization to catalysis of the severe acute respiratory syndrome coronavirus 3C-like protease","volume":"82","author":"Shi","year":"2008","journal-title":"J. Virol."},{"key":"2024080512071844200_B236","doi-asserted-by":"publisher","first-page":"9347","DOI":"10.1080\/07391102.2021.1927845","article-title":"Proposition of a new allosteric binding site for potential SARS-CoV-2 3CL protease inhibitors by utilizing molecular dynamics simulations and ensemble docking","volume":"40","author":"Novak","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"2024080512071844200_B237","doi-asserted-by":"publisher","first-page":"25428","DOI":"10.1002\/anie.202109965","article-title":"NMR Spectroscopy of the Main Protease of SARS-CoV-2 and Fragment-Based Screening Identify Three Protein Hotspots and an Antiviral Fragment","volume":"60","author":"Cantrelle","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2024080512071844200_B238","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1021\/acs.jpclett.0c03182","article-title":"Candidate binding sites for allosteric inhibition of the SARS-CoV-2 main protease from the analysis of large-scale molecular dynamics simulations","volume":"12","author":"Carli","year":"2021","journal-title":"J. Physical Chem. Lett."},{"key":"2024080512071844200_B239","doi-asserted-by":"publisher","first-page":"20200591","DOI":"10.1098\/rsif.2020.0591","article-title":"Computational analysis of dynamic allostery and control in the SARS-CoV-2 main protease","volume":"18","author":"Dubanevics","year":"2021","journal-title":"J. R. Soc. Interface"},{"key":"2024080512071844200_B240","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.2147\/DDDT.S370574","article-title":"Allosteric binding sites of the SARS-CoV-2 main protease: potential targets for broad-spectrum anti-coronavirus agents","volume":"16","author":"Alzyoud","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"2024080512071844200_B241","doi-asserted-by":"publisher","first-page":"6603","DOI":"10.1080\/07391102.2021.1891141","article-title":"Targeting allosteric pockets of SARS-CoV-2 main protease M(pro)","volume":"40","author":"Bhat","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"2024080512071844200_B242","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1021\/acs.jcim.1c00449","article-title":"Dynamic profiling of \u03b2-coronavirus 3CL M(pro) protease ligand-binding sites","volume":"61","author":"Cho","year":"2021","journal-title":"J. Chem. Inf. Model."},{"issue":"3","key":"2024080512071844200_B243","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.3390\/ijms24032651","article-title":"Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities","volume":"24","author":"Zubair","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"2024080512071844200_B244","doi-asserted-by":"publisher","first-page":"5100","DOI":"10.1158\/1078-0432.CCR-15-0313","article-title":"Cyclin-dependent kinase inhibitor AT7519 as a potential drug for MYCN-dependent neuroblastoma","volume":"21","author":"Dolman","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"2024080512071844200_B245","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1310\/hpj4806-494","article-title":"Apixaban","volume":"48","author":"Cada","year":"2013","journal-title":"Hosp. Pharm."},{"issue":"6","key":"2024080512071844200_B246","doi-asserted-by":"publisher","first-page":"mjac039","DOI":"10.1093\/jmcb\/mjac039","article-title":"Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way","volume":"14","author":"Chaves","year":"2022","journal-title":"J. Mol. Cell Biol."},{"key":"2024080512071844200_B247","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.05.026","article-title":"Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics","author":"Chan","year":"2024","journal-title":"Acta Pharmaceutica Sinica B."},{"key":"2024080512071844200_B248","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.ijbiomac.2022.09.204","article-title":"Agathisflavone, a natural biflavonoid that inhibits SARS-CoV-2 replication by targeting its proteases","volume":"222","author":"Chaves","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"2024080512071844200_B249","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41596-021-00659-2","article-title":"Artificial intelligence-enabled virtual screening of ultra-large chemical libraries with deep docking","volume":"17","author":"Gentile","year":"2022","journal-title":"Nat. Protoc."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20231395\/959707\/bsr-2023-1395c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20231395\/959707\/bsr-2023-1395c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T12:18:03Z","timestamp":1722860283000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/44\/8\/BSR20231395\/234719\/3-chymotrypsin-like-protease-in-SARS-CoV-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":249,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,28]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20231395","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,8]]},"article-number":"BSR20231395"}}